MARKET

VVUS

VVUS

VIVUS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.400
+0.060
+4.48%
After Hours: 1.410 +0.01 +0.71% 19:52 04/03 EDT
OPEN
1.410
PREV CLOSE
1.340
HIGH
1.470
LOW
1.370
VOLUME
1.64M
TURNOVER
--
52 WEEK HIGH
4.750
52 WEEK LOW
0.8000
MARKET CAP
14.91M
P/E (TTM)
-0.4729
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VVUS stock price target is 1.750 with a high estimate of 1.750 and a low estimate of 1.750.

EPS

VVUS News

More
  • VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
  • GlobeNewswire · 19h ago
  • TSLA, ET among premarket gainers
  • Seeking Alpha - Article · 1d ago
  • VitalTech Partners with VIVUS Pharmaceuticals to Accelerate Launch of Telehealth and Remote Patient Monitoring Modules
  • PR Newswire · 1d ago
  • Mid-Afternoon Market Update: Dow Tumbles 800 Points; Chembio Diagnostics Shares Spike Higher
  • Benzinga · 2d ago

Industry

Pharmaceuticals
-0.14%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About VVUS

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
More

Webull offers kinds of VIVUS, Inc. stock information, including NASDAQ:VVUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VVUS stock news, and many more online research tools to help you make informed decisions.